Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.

Maxwell J LaskoDavid P NicolauTomefa E Asempa

Published in: The Journal of antimicrobial chemotherapy (2021)

Humanized exposures of cefepime/taniborbactam achieved robust killing of Enterobacterales, P. aeruginosa and S. maltophilia harbouring ESBL, AmpC, KPC and/or OXA-48. These data support the role of cefepime/taniborbactam for cUTI treatment for cefepime/taniborbactam MICs up to 32 mg/L.

Keyphrases

gram negative
klebsiella pneumoniae
multidrug resistant
urinary tract infection
acinetobacter baumannii
drug resistant
escherichia coli
air pollution
electronic health record
big data
combination therapy